Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | GALR2 | O43603 | 1/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | XBP1 | P17861 | 1/20 | 0.62 |
| ▸ | CCR6 | P51684 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766271 | 0.81 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL768128 | 0.80 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL6502811 | 0.75 | KMT2A (0.65) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL1975251 | 0.75 | LMNA (0.45) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL27507150 | 0.75 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL1966149 | 0.73 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL11244929 | 0.72 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL11418690 | 0.72 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL6169348 | 0.72 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 | |
| SCHEMBL1725104 | 0.72 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2POLBLMNAGALR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066673-B1 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE CORP (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-8063225-B2 | 2-(4-(3-(2,4-Dimethylphenoxy)-2-hydroxypropylamino)-2-oxo-1,2-dihydropyridin-3-yl)-6-(1-methylpiperidin-4-yl)-6,7-dihydroimidazo[4,5-f]isoindol-5(1H)-one; modulating tyrosine kinase; enzyme inhibitors; cancer, diabetes, restenosis, arteriosclerosis, psoriasis, angiogenic diseases, immunologic disorders | CHEMBRIDGE CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2066673-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071473-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | ALDH1A1 1899/4885SMN1; SMN2 2866/4885POLB 1790/4885 |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | ALDH1A1 1899/4885SMN1; SMN2 2866/4885POLB 1790/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | ALDH1A1 1899/4885SMN1; SMN2 2866/4885POLB 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.